Rallybio Stockholders Approve Avenzo Merger, Name Change and Reverse Split
Rallybio Corp RLYB
$15.45
▼ -1.34%
($-0.21)
⬇️ Below Yest. Low
🎈 Low Float
Open
$15.67
Prev Close
$15.66
Day Range
$15.28 – $15.68
52W Range
$3.67 – $17.57
Market Cap
$84.31M
P/E (TTM)
1.85
Beta
-0.66
EPS (TTM)
$7.89
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-07-29 |
| Shares Out. | 5,380,000 |
| Website | rallybio.com ↗ |
| Phone | 12038593820 |
| Employees | 6 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$2.7M |
| Free Cash Flow | $31.0M |
| Total Assets | $95.6M |
| Total Liabilities | $3.3M |
| Equity | $92.3M |
About Rallybio Corp
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
Rallybio Corp is a publicly traded company under the ticker symbol RLYB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2026-11-01)